Low-Dose Drug Regimen Is Effective for Older, Frail Patients With Gastroesophageal Cancer
May 16th 2019A group of researchers in the UK sought out to determine the efficacy of a reduced-dose regimen of oxaliplatin (Eloxatin) and capecitabine (Xeloda) in this patient population through the randomized, phase III GO2 clinical trial.
Pembrolizumab Shows OS Benefit in PD-L1+ Esophageal Cancer
January 26th 2019Pembrolizumab (Keytruda) was found to reduce the risk of death by 31% in patients with PD-L1–positive (combined positive score [CPS] ≥10) advanced or metastatic esophageal or esophageal junction carcinoma who progressed on standard therapy, according to phase III findings of the KEYNOTE-181 trial.
Nivolumab Extends Survival in Advanced or Recurrent Esophageal Cancer
January 18th 2019Nivolumab (Opdivo) significantly improved overall survival (OS) versus chemotherapy in patients with unresectable advanced or recurrent esophageal cancer that is refractory to or intolerant of fluoropyrimidine plus platinum-based therapy, according to topline findings of the phase III ATTRACTION-3 study.
BLU-667 Shows Clinical Benefit in Advanced, RET-Altered Solid Tumors
April 20th 2018BLU-667 appeared to be well-tolerated and had broad clinical benefit among patients with advanced, RET-altered solid tumors who progressed on prior therapies, according to study findings from a phase I clinical trial presented at the AACR Annual Meeting 2018.
Treatment Informed by PET Imaging Linked to Better Response Rates in Esophageal Cancer
January 18th 2017Patients with esophogeal cancers who received induction chemotherapy, followed by PET imaging to determine whether alternative chemotherapy was needed had improved pathologic complete response rates
Complete Responses With Reduced-Dose Radiation in HPV-Linked Oropharynx Cancers
January 10th 2017For patients with HPV-related oropharyngeal squamous cell carcinoma, induction chemotherapy plus reduced-dose radiation and weekly cetuximab brought improvements for swallowing and nutritional status along with complete clinical responses.
Oral HPV Test Shows Potential for Predicting Oropharyngeal Cancer Risk
January 30th 2016Individuals with detectable human papillomavirus (HPV)-16 in their mouthwash samples were 22 times more likely to develop oropharyngeal cancer (OPC) than those without the type of virus, according to findings of a new study.